Livent (LTHM) 10-Q 3 Nov 22 2022 Q3 Quarterly report Financial data

Cover page

Cover page	9 Months Ended
	Sep. 30, 2022 shares
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity File Number	001-38694
Entity Registrant Name	LIVENT CORPORATION
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	82-4699376
Entity Address, Address Line One	1818 Market Street
Entity Address, City or Town	Philadelphia
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19103
City Area Code	215
Local Phone Number	299-5900
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	LTHM
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	179,373,751
Entity Central Index Key	0001742924
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Amendment Flag	false

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Revenue	$ 231,600,000	$ 103,600,000	$ 593,800,000	$ 297,500,000
Cost of sales	112,200,000	85,300,000	312,000,000	245,500,000
Gross margin	119,400,000	18,300,000	281,800,000	52,000,000
Selling, general and administrative expenses	15,000,000	11,800,000	40,600,000	34,200,000
Research and development expenses	900,000	800,000	2,600,000	2,200,000
Restructuring and other charges	700,000	1,100,000	4,600,000	3,400,000
Separation-related costs	100,000	800,000	500,000	1,300,000
Total costs and expenses	128,900,000	99,800,000	360,300,000	286,600,000
Income from operations before equity in net loss of unconsolidated affiliate, interest expense, net, loss on debt extinguishment and other gain	102,700,000	3,800,000	233,500,000	10,900,000
Equity in net loss of unconsolidated affiliate	3,500,000	1,000,000	8,400,000	3,700,000
Interest expense, net	0	0	0	300,000
Loss on debt extinguishment	100,000	0	100,000	0
Other gain	0	0	22,200,000	0
Income from operations before income taxes	99,100,000	2,800,000	247,200,000	6,900,000
Income tax expense	21,500,000	15,400,000	56,400,000	13,800,000
Net income/(loss)	$ 77,600,000	$ (12,600,000)	$ 190,800,000	$ (6,900,000)
Net income/(loss) per weighted average share - basic (in dollars per share)	$ 0.43	$ (0.08)	$ 1.13	$ (0.05)
Net income/(loss) per weighted average share - diluted (in dollars per share)	$ 0.37	$ (0.08)	$ 0.96	$ (0.05)
Weighted average common shares outstanding - basic (in shares)	179.3	161.6	169.3	152.3
Weighted average common shares outstanding - diluted (in shares)	209.4	161.6	199.2	152.3

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME/(LOSS) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Statement of Comprehensive Income [Abstract]
Net income/(loss)	$ 77,600,000	$ (12,600,000)	$ 190,800,000	$ (6,900,000)
Foreign currency adjustments:
Foreign currency translation loss arising during the period	(6,100,000)	(1,100,000)	(11,500,000)	(200,000)
Total foreign currency translation adjustments	(6,100,000)	(1,100,000)	(11,500,000)	(200,000)
Derivative instruments:
Unrealized hedging losses, net of tax of less than $0.1, less than $0.1, zero, and zero	(100,000)	(100,000)	0	0
Reclassification of deferred losses included in net income/(loss), net of tax of $(0.1), zero, $(0.1) and zero	300,000	0	200,000	0
Total derivative instruments, net of tax of $(0.1), less than $0.1, $(0.1), and zero	200,000	(100,000)	200,000	0
Other comprehensive loss, net of tax	(5,900,000)	(1,200,000)	(11,300,000)	(200,000)
Comprehensive income/(loss)	$ 71,700,000	$ (13,800,000)	$ 179,500,000	$ (7,100,000)

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME/(LOSS) (Parenthetical) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Statement of Comprehensive Income [Abstract]
Unrealized hedging losses, tax	$ 0.1	$ 0.1	$ 0	$ 0
Reclassification of deferred hedging losses included in net income, tax	(0.1)	0	(0.1)	0
Total derivative instruments loss, tax	$ (0.1)	$ 0.1	$ (0.1)	$ 0

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 211.6	$ 113
Trade receivables, net of allowance of approximately $0.3 in 2022 and $0.3 in 2021	164	96.4
Inventories, net	141.8	134.6
Prepaid and other current assets	56.5	55.3
Total current assets	573.9	399.3
Investments	433.9	27.2
Property, plant and equipment, net of accumulated depreciation of $248.3 in 2022 and $243.0 in 2021	882.2	677.9
Deferred income taxes	0.5	0.9
Right of use assets - operating leases, net	4.9	6.3
Other assets	111.9	90.9
Total assets	2,007.3	1,202.5
Current liabilities
Current portion of long-term debt	13.5	0
Accounts payable, trade and other	72.2	65.4
Accrued and other liabilities	68.9	61.8
Operating lease liabilities - current	1	1.1
Income taxes	7.4	3
Total current liabilities	163	131.3
Long-term debt	241.6	240.4
Operating lease liabilities - long-term	4.1	5.4
Environmental liabilities	5.7	5.6
Deferred income taxes	23.6	12.7
Contract liability - long-term	198	0
Other long-term liabilities	16.7	11.7
Commitments and contingent liabilities (Note 13)	0	0
Total current and long-term liabilities	652.7	407.1
Equity
Common stock; $0.001 par value; 2 billion shares authorized; 179,476,829 and 161,791,602 shares issued; 179,373,751 and 161,689,984 outstanding as of September 30, 2022 and December 31, 2021, respectively	0.1	0.1
Capital in excess of par value of common stock	1,157.8	778.1
Retained earnings	251.7	60.9
Accumulated other comprehensive loss	(54.2)	(42.9)
Treasury stock, at cost; 103,078 and 101,618 shares as of September 30, 2022 and December 31, 2021, respectively	(0.8)	(0.8)
Total equity	1,354.6	795.4
Total liabilities and equity	$ 2,007.3	$ 1,202.5

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Current assets
Allowance for trade receivables	$ 0.3	$ 0.3
Accumulated depreciation	$ 248.3	$ 243
Equity
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	2,000,000,000	2,000,000,000
Common stock, shares issued (in shares)	179,476,829	161,791,602
Common stock, outstanding (in shares)	179,373,751	161,689,984
Treasury Stock, Common, Shares	(103,078)	(101,618)

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)		9 Months Ended
		Sep. 30, 2022	Sep. 30, 2021
Cash provided by operating activities:
Net income/(loss)		$ 190,800,000	$ (6,900,000)
Adjustments to reconcile net income/(loss) to cash provided by operating activities:
Depreciation and amortization		19,400,000	18,700,000
Restructuring and other charges/(income)		4,400,000	(800,000)
Deferred income taxes		11,300,000	11,200,000
Separation-related income		(400,000)	0
Share-based compensation		5,200,000	4,000,000
Change in investments in trust fund securities		600,000	400,000
Deferred financing fees amortization		0	300,000
Equity in net loss of unconsolidated affiliate		8,400,000	3,700,000
Other gain		(22,200,000)	0
Other non-cash adjustments		200,000	0
Changes in operating assets and liabilities:
Trade receivables, net		(76,700,000)	(6,200,000)
Inventories		(14,400,000)	(4,200,000)
Accounts payable, trade and other		11,100,000	5,500,000
Changes in deferred compensation		(600,000)	1,200,000
Increase		198,000,000	0
Income taxes		4,800,000	2,300,000
Change in prepaid and other current assets and other assets		(25,200,000)	16,600,000
Change in accrued and other current and long-term liabilities		13,500,000	(4,800,000)
Cash provided by operating activities		328,200,000	41,000,000
Cash used in investing activities:
Capital expenditures	[1]	(228,300,000)	(69,400,000)
Investments in Livent NQSP securities		(100,000)	(1,200,000)
Proceeds from Blue Chip Swap, net of purchases		22,200,000	0
Investment in unconsolidated affiliate		(17,700,000)	(2,500,000)
Other investing activities		(1,800,000)	(1,200,000)
Cash used in investing activities		(225,700,000)	(74,300,000)
Cash (used in)/provided by financing activities:
Proceeds from Revolving Credit Facility		13,000,000	39,500,000
Repayments of Revolving Credit Facility		(13,000,000)	(75,100,000)
Proceeds from Offering		0	261,600,000
Payments of financing fees - Revolving Credit Facility		(2,200,000)	0
Payments of underwriting fees and expenses - Offering		0	(9,400,000)
Proceeds from issuance of common stock - incentive plans		1,200,000	300,000
Cash (used in)/provided by financing activities		(1,000,000)	216,900,000
Effect of exchange rate changes on cash and cash equivalents		(2,900,000)	100,000
Increase in cash and cash equivalents		98,600,000	183,700,000
Cash and cash equivalents, beginning of period		113,000,000	11,600,000
Cash and cash equivalents, end of period		211,600,000	195,300,000
Supplemental Disclosure for Cash Flow:
Cash payments for income taxes, net of refunds		35,800,000	500,000
Cash payments for interest, net	[1]	12,100,000	12,900,000
Cash (receipts)/payments for Restructuring and other charges		(100,000)	4,200,000
Cash payments for Separation-related charges		900,000	1,400,000
Accrued capital expenditures		30,700,000	17,800,000
Accrued investment in unconsolidated affiliate		16,600,000	0
Non-cash investment in unconsolidated affiliates		387,100,000	0
Operating lease right-of-use assets and lease liabilities recorded for ASC 842		$ 0	$ 2,100,000
[1] For the nine months ended September 30, 2022, and 2021 $12.0 million and $11.5 million of interest expense was capitalized, respectively.

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Statement of Cash Flows [Abstract]
Interest expense capitalized	$ 12	$ 11.5

CONDENSED CONSOLIDATED STATEM_6

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY - USD ($)	Total	Common Stock, $0.001 Per Share Par Value	Capital In Excess of Par	Retained Earnings	Accumulated Other Comprehensive Loss	Treasury Stock
Beginning balance at Dec. 31, 2020	$ 536,200,000	$ 100,000	$ 520,900,000	$ 60,300,000	$ (44,400,000)	$ (700,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income/(loss)	(800,000)			(800,000)
Stock compensation plans	1,200,000		1,200,000
Exercise of stock options	200,000		200,000
Foreign currency translation adjustments	(300,000)				(300,000)
Shares withheld for taxes - common stock issuances	(800,000)		(800,000)
Net purchases of treasury stock - Livent NQSP	(100,000)					(100,000)
Ending balance at Mar. 31, 2021	535,600,000	100,000	521,500,000	59,500,000	(44,700,000)	(800,000)
Beginning balance at Dec. 31, 2020	536,200,000	100,000	520,900,000	60,300,000	(44,400,000)	(700,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income/(loss)	(6,900,000)
Net hedging gains (losses), net of income tax	0
Foreign currency translation adjustments	(200,000)
Reclassification of deferred hedging gains, net of income tax	0
Ending balance at Sep. 30, 2021	784,500,000	100,000	776,400,000	53,400,000	(44,600,000)	(800,000)
Beginning balance at Mar. 31, 2021	535,600,000	100,000	521,500,000	59,500,000	(44,700,000)	(800,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income/(loss)	6,500,000			6,500,000
Stock compensation plans	1,400,000		1,400,000
Net hedging gains (losses), net of income tax	100,000				100,000
Foreign currency translation adjustments	1,200,000				1,200,000
Issuance of common stock - Offering	252,300,000		252,300,000
Ending balance at Jun. 30, 2021	797,100,000	100,000	775,200,000	66,000,000	(43,400,000)	(800,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income/(loss)	(12,600,000)			(12,600,000)
Stock compensation plans	1,400,000		1,400,000
Exercise of stock options	100,000		100,000
Net hedging gains (losses), net of income tax	(100,000)				(100,000)
Foreign currency translation adjustments	(1,100,000)				(1,100,000)
Issuance of common stock - Offering	(100,000)		(100,000)
Shares withheld for taxes - common stock issuances	(200,000)		(200,000)
Reclassification of deferred hedging gains, net of income tax	0
Ending balance at Sep. 30, 2021	784,500,000	100,000	776,400,000	53,400,000	(44,600,000)	(800,000)
Beginning balance at Dec. 31, 2021	795,400,000	100,000	778,100,000	60,900,000	(42,900,000)	(800,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income/(loss)	53,200,000			53,200,000
Stock compensation plans	1,700,000		1,700,000
Exercise of stock options	100,000		100,000
Net hedging gains (losses), net of income tax	100,000				100,000
Foreign currency translation adjustments	(1,000,000)				(1,000,000)
Shares withheld for taxes - common stock issuances	(500,000)		(500,000)
Ending balance at Mar. 31, 2022	849,000,000	100,000	779,400,000	114,100,000	(43,800,000)	(800,000)
Beginning balance at Dec. 31, 2021	795,400,000	100,000	778,100,000	60,900,000	(42,900,000)	(800,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income/(loss)	190,800,000
Net hedging gains (losses), net of income tax	0
Foreign currency translation adjustments	(11,500,000)
Reclassification of deferred hedging gains, net of income tax	200,000
Ending balance at Sep. 30, 2022	1,354,600,000	100,000	1,157,800,000	251,700,000	(54,200,000)	(800,000)
Beginning balance at Mar. 31, 2022	849,000,000	100,000	779,400,000	114,100,000	(43,800,000)	(800,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income/(loss)	60,000,000			60,000,000
Stock compensation plans	1,800,000		1,800,000
Exercise of stock options	200,000		200,000
Foreign currency translation adjustments	(4,400,000)				(4,400,000)	0
Issuance of common stock - QLP Merger	373,900,000		373,900,000
Shares withheld for taxes - common stock issuances	(200,000)		(200,000)
Reclassification of deferred hedging gains, net of income tax	(100,000)				(100,000)
Net purchases of treasury stock - Livent NQSP	(100,000)					(100,000)
Ending balance at Jun. 30, 2022	1,280,100,000	100,000	1,155,100,000	174,100,000	(48,300,000)	(900,000)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income/(loss)	77,600,000			77,600,000
Stock compensation plans	1,800,000		1,800,000
Exercise of stock options	900,000		900,000
Net hedging gains (losses), net of income tax	(100,000)				(100,000)
Foreign currency translation adjustments	(6,100,000)				(6,100,000)
Net sales of treasury stock - Livent NQSP	100,000					100,000
Reclassification of deferred hedging gains, net of income tax	300,000				300,000
Ending balance at Sep. 30, 2022	$ 1,354,600,000	$ 100,000	$ 1,157,800,000	$ 251,700,000	$ (54,200,000)	$ (800,000)

CONDENSED CONSOLIDATED STATEM_7

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (Parenthetical) - $ / shares	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020
Statement of Stockholders' Equity [Abstract]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001

Description of the Business

Description of the Business	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of the Business	Description of the Business Background and Nature of Operations Livent Corporation (“Livent”, “we”, “us”, "Company" or “our”) manufactures a wide range of lithium products, which are used primarily in lithium-based batteries, specialty polymers and chemical synthesis applications. We serve a diverse group of markets. A major growth driver for lithium in the future will be the increasing adoption of electric vehicles ("EVs") and other energy storage applications.

Principal Accounting Policies a

Principal Accounting Policies and Related Financial Information	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Principal Accounting Policies and Related Financial Information	Principal Accounting Policies and Related Financial Information The accompanying condensed consolidated financial statements were prepared in accordance with the requirements of the Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules, certain notes or other financial information that are normally required by U.S. GAAP have been condensed or omitted from these interim financial statements. The financial statements included in this report reflect all normal and recurring adjustments which, in the opinion of management, are necessary for a fair presentation of our condensed consolidated financial position as of September 30, 2022 and December 31, 2021, the condensed consolidated results of operations, the condensed consolidated statement of comprehensive income/(loss) and the condensed consolidated statement of changes in equity for the three and nine months ended September 30, 2022 and 2021, and the condensed consolidated cash flows for the nine months ended September 30, 2022 and 2021. The unaudited results of operations for the interim periods reported are not necessarily indicative of results to be expected for the full year. These statements, therefore, should be read in conjunction with the annual consolidated financial statements and related notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the "2021 Annual Report on Form 10-K"). Blue Chip Swap. Our wholly owned subsidiary in Argentina uses the U.S. dollar as their functional currency. Argentina peso-denominated monetary assets and liabilities are remeasured at each balance sheet date to the official currency exchange rate then in effect which represents the exchange rate available for external commerce (import payments and export collections) and financial payments, with currency remeasurement and other transaction gains and losses recognized in earnings. In September 2019, the President of Argentina reinstituted exchange controls restricting foreign currency purchases in an attempt to stabilize Argentina’s financial markets. As a result, a legal trading mechanism known as the Blue Chip Swap emerged in Argentina for all individuals or entities to transfer U.S. dollars out of and into Argentina. The Blue Chip Swap rate is the implicit exchange rate resulting from the Blue Chip Swap transaction. Recently, the Blue Chip Swap rate has diverged significantly from Argentina’s official rate due to the economic environment. During the first half of 2022, to support our capital expansion projects, we transferred U.S. dollars into Argentina through the Blue Chip Swap method whereby our wholly owned Delaware subsidiary, MDA Lithium Holdings LLC, realized a gain from the purchase in U.S. dollars and sale in Argentina pesos of Argentina Sovereign U.S. dollar-denominated bonds. The gain of U.S. $22.2 million for the nine months ended September 30, 2022, was recorded to Other gain in our condensed consolidated statement of operations. There were no Blue Chip Swap transactions for the three months ended September 30, 2022. Performance-Based Restricted Stock Unit ("PRSU") Awards. The Company granted approximately sixty-three thousand PRSUs ("2022 PRSUs") to key employees on February 23, 2022, as authorized under the provisions of the Livent Corporation 2018 Incentive Compensation and Stock Plan. The number of PRSUs ultimately earned will be based on Livent's Total Shareholder Return ("TSR") relative to the TSR of the companies in the Russell 3000 Chemical Supersector Index over a three year performance period from January 1, 2022 through December 31, 2024 (the "Performance Period"). The final number of PRSUs earned will range from 0% to 200% of the number of PRSUs granted based on the Company's relative TSR performance over the Performance Period. Because the value of the 2022 PRSUs is dependent upon the attainment of a level of TSR, it requires the impact of the market condition to be considered when estimating the fair value of the 2022 PRSUs. As a result, the Monte Carlo model is applied and the most significant valuation assumptions used related to the 2022 PRSUs during the year ending December 31, 2022, include: Valuation date stock price $21.01 Expected volatility 72.99% Risk free rate 1.74% The February 23, 2022 grant date fair value of each PRSU granted was $20.82 per share.

Recently Issued and Adopted Acc

Recently Issued and Adopted Accounting Pronouncements and Regulatory Items	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Recently Issued and Adopted Accounting Pronouncements and Regulatory Items	Recently Issued and Adopted Accounting Pronouncements and Regulatory Items New accounting guidance and regulatory items In November 2021, the Financial Accounting Standard Board ("FASB") issued ASU No. 2021-10, Government Assistance (Topic 832) . This ASU requires business entities to disclose information about government assistance they receive if the transactions were accounted for by analogy to either a grant or a contribution accounting model. The disclosure requirements include the nature of the transaction and the related accounting policy used, the line items on the balance sheets and statements of operations that are affected and the amounts applicable to each financial statement line item and the significant terms and conditions of the transactions. The ASU is effective for annual periods beginning after December 15, 2021. The disclosure requirements can be applied either retrospectively or prospectively to all transactions in the scope of the amendments that are reflected in the financial statements at the date of initial application and new transactions that are entered into after the date of initial application. We are evaluating the impact of this ASU on our consolidated financial statements. In April 2020, FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848). T he amendments in this ASU provide optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. An entity may optionally elect to apply the amendments effective in the first interim period that includes or is subsequent to March 12, 2020 through December 31, 2022. We do not expect adoption to have material impact on our condensed consolidated financial statements.

Revenue Recognition

Revenue Recognition	9 Months Ended
	Sep. 30, 2022
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition Disaggregation of revenue We disaggregate revenue from contracts with customers by geographical areas (based on product destination) and by product categories. The following table provides information about disaggregated revenue by major geographical region: (in Millions) Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 North America (1) (2) $ 46.8 $ 15.9 $ 109.3 $ 44.2 Latin America 0.7 — 1.8 — Europe, Middle East & Africa 30.1 14.2 76.8 46.0 Asia Pacific (1) (2) 154.0 73.5 405.9 207.3 Total Revenue $ 231.6 $ 103.6 $ 593.8 $ 297.5 1. During the three months ended September 30, 2022, countries with sales in excess of 10% of combined revenue consisted of Japan, the U.S., and China. Sales for the three months ended September 30, 2022 for Japan, the U.S., and China totaled $39.2 million, $45.1 million, $85.0 million, respectively. During the nine months ended September 30, 2022, countries with sales in excess of 10% of combined revenue consisted of Japan, the U.S., and China. Sales for the nine months ended September 30, 2022 for Japan, the U.S., and China totaled $124.1 million, $105.6 million, $208.8 million, respectively. During the three months ended September 30, 2021, countries with sales in excess of 10% of combined revenue consisted of Japan, the U.S. and China. Sales for the three months ended September 30, 2021 for Japan, the U.S. and China totaled $24.5 million, $15.6 million and $36.6 million, respectively. During the nine months ended September 30, 2021, countries with sales in exce ss of 10% of combined revenue consisted of Japan, South Korea, the U.S. and China . Sales for the nine months ended September 30, 2021 for Japan, South Korea, the U.S. and China totaled $65.1 million, $38.1 million, $43.5 million and $89.9 million, respectively . 2. In the fourth quarter of 2021, we reclassified certain revenue from the nine months ended September 30, 2021 from North America to Asia Pacific to present revenue based on product destination. For the three months ended September 30, 2022, one customer accounted for approximately 22% of total revenue and our 10 largest customers accounted in aggregate for approximately 62% of total revenue. For the three months ended September 30, 2021, one customer accounted for approximately 35% of total revenue and our 10 largest customers accounted in aggregate for approximately 69% of total revenue. For the nine months ended September 30, 2022, one customer accounted for approximately 23% of total revenue and our 10 largest customers accounted in aggregate for approximately 61% of total revenue. For the nine months ended September 30, 2021, one customer accounted for approximately 36% of total revenue and our 10 largest customers accounted in aggregate for approximately 68% of total revenue. A loss of any material customer could have a material adverse effect on our business, financial condition and results of operations. The following table provides information about disaggregated revenue by major product category: (in Millions) Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Lithium Hydroxide $ 118.4 $ 50.7 $ 299.5 $ 160.5 Butyllithium 88.2 27.4 203.1 76.1 High Purity Lithium Metal and Other Specialty Compounds 11.9 9.8 42.0 27.6 Lithium Carbonate and Lithium Chloride 13.1 15.7 49.2 33.3 Total Revenue $ 231.6 $ 103.6 $ 593.8 $ 297.5 Contract asset and contract liability balances The following table presents the opening and closing balances of our receivables, net of allowances and contract liabilities from contracts with customers. As o f December 31, 2021, there were no significant contract liabilities recorded in the condensed consolidated balance sheets. (in Millions) Balance as of September 30, 2022 Balance as of December 31, 2021 Increase Receivables from contracts with customers, net of allowances $ 164.0 $ 96.4 $ 67.6 Contract liability - long-term $ 198.0 $ — $ 198.0 The balance of receivables from contracts with customers listed in the table above represents the current trade receivables, net of allowance for doubtful accounts. The allowance for receivables represents our best estimate of the probable losses associated with potential customer defaults. We determine the allowance based on historical experience, current collection trends, and external business factors such as economic factors, including regional bankruptcy rates, and political factors. Performance obligations Occasionally, we may enter into multi-year take or pay supply agreements with customers. The aggregate amount of revenue expected to be recognized related to these contracts’ performance obligations that are unsatisfied or partially unsatisfied is approximately $713 million in the next three years. These approximate revenues do not include amounts of variable consideration attributable to contract renewals or contract contingencies. Based on our past experience with the customers under these arrangements, we expect to continue recognizing revenue in accordance with the contracts as we transfer control of the product to the customer. However, in the case a shortfall of volume purchases occurs, we will recognize the amount payable by the customer over the remaining performance obligations in the contract.

Inventories, Net

Inventories, Net	9 Months Ended
	Sep. 30, 2022
Inventory Disclosure [Abstract]
Inventories, Net	Inventories, Net Inventories consisted of the following: (in Millions) September 30, 2022 December 31, 2021 Finished goods $ 55.6 $ 52.2 Semi-finished goods 56.4 43.6 Raw materials, supplies, and other 29.8 38.8 Inventory, net $ 141.8 $ 134.6

Investments

Investments	9 Months Ended
	Sep. 30, 2022
Equity Method Investments and Joint Ventures [Abstract]
Investments	Investments On June 6, 2022, Livent closed on the Transaction Agreement and Plan of Merger (the "QLP Merger") with The Pallinghurst Group ("Pallinghurst") to provide Livent with a direct 50% ownership interest in the Nemaska Project, a fully integrated lithium chemical asset located in Québec, Canada that is not yet in commercial production. The Company issued 17,500,000 shares of its common stock to acquire the remaining 50% share of Québec Lithium Partners (UK) Limited ("QLP") previously owned by Pallinghurst and certain of its investors. Upon consummation of the QLP Merger, Livent recorded an Investment of $387.1 million, Cash and cash equivalents of $0.3 million and Short-term debt of $13.5 million, representing QLP's equity method investment in the Nemaska Project, cash on hand, and debt, respectively, with a corresponding increase to additional paid in capital of $373.9 million in its condensed consolidated balance sheet. Livent now owns a 50% equity interest in the Nemaska Project through its ownership of QLP. The Canadian government, through Investissement Québec (“IQ”), continues to own the remaining 50% interest in the Nemaska Project. The Company accounts for the investment in the Nemaska Project as an equity method investment on a one-quarter lag basis and it is included in Investments in our condensed consolidated balance sheets. For the three and nine months ended

Restructuring and Other Charges

Restructuring and Other Charges	9 Months Ended
	Sep. 30, 2022
Restructuring and Related Activities [Abstract]
Restructuring and Other Charges	Restructuring and Other Charges The following table shows other charges included in "Restructuring and other charges" in the condensed consolidated statements of operations: Three Months Ended September 30, Nine Months Ended September 30, (in Millions) 2022 2021 2022 2021 Restructuring charges: Severance-related and exit costs (1) $ 0.4 $ 0.1 $ 0.9 $ 0.2 Other charges: Environmental remediation (2) 0.1 0.1 0.3 0.3 Other (3) 0.2 0.9 3.4 2.9 Total Restructuring and other charges $ 0.7 $ 1.1 $ 4.6 $ 3.4 ___________________ 1. The three and nine months ended September 30, 2022 includes severance costs for management changes at certain administrative facilities. 2. There is one environmental remediation site in Bessemer City, North Carolina.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes We determine our interim tax provision using an estimated annual effective tax rate methodology (“EAETR”) in accordance with U.S. GAAP. The EAETR is applied to the year-to-date ordinary income, exclusive of discrete items. The tax effects of discrete items are then included to arrive at the total reported interim tax provision. The determination of the EAETR is based upon a number of estimates, including the estimated annual pretax ordinary income in each tax jurisdiction in which we operate. As our projections of ordinary income change throughout the year, the EAETR will change period-to-period. The tax effects of discrete items are recognized in the tax provision in the period they occur in accordance with U.S. GAAP. Depending on various factors, such as the item’s significance in relation to total income and the rate of tax applicable in the jurisdiction to which it relates, discrete items in any quarter can materially impact the reported effective tax rate. As a global enterprise, our tax expense can be impacted by changes in tax rates or laws, the finalization of tax audits and reviews, as well as other factors. As a result, there can be significant volatility in interim tax provisions.

Debt

Debt	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Debt	Debt Long-term debt Long-term debt consists of the following: Interest Rate Percentage Maturity September 30, 2022 December 31, 2021 (in Millions) SOFR borrowings Base rate borrowings Revolving Credit Facility (1) 4.89% 7.0% 2027 $ — $ — Deferred Payment Note 8.0% 2022 13.5 — 4.125% Convertible Senior Notes due 2025 4.125% 2025 245.8 245.8 Transaction costs - 2025 Notes (4.2) (5.4) Subtotal long-term debt (including current maturities) 255.1 240.4 Less current maturities (13.5) — Total long-term debt $ 241.6 $ 240.4 ______________________________ 1. As of September 30, 2022 and December 31, 2021, there were $14.5 million in letters of credit outstanding under our Revolving Credit Facility and $485.5 million available funds as of September 30, 2022 and December 31, 2021. Fund availability is subject to the Company meeting its debt covenants. Deferred Payment Note ("QLP Note") Prior to becoming our wholly owned subsidiary pursuant to the QLP Merger, on November 26, 2020, QLP entered into the QLP Note to defer $12.5 million of its investment commitment for its 50% share of the Nemaska Project. Upon our acquisition of the remaining share of QLP in June 2022, the QLP Note became the sole liability of Livent. The QLP Note, payable to Nemaska Lithium Shawinigan Transformation Inc., matures on November 26, 2022, is classified as Current portion of long-term debt in our condensed consolidated balance sheets and earns coupon interest at an annual rate of 8%, compounded to the principal monthly, for the first twelve months. This interest is payable at the maturity date, along with the principal. From November 26, 2021, interest on the note accrues and is payable monthly. On October 14, 2022, QLP paid Nemaska Lithium Shawinigan cash of $13.5 million to repay the QLP Note. 2025 Notes In the third quarter of 2022, the holders of the 2025 Notes were notified that the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on, and including, September 30, 2022 was greater than or equal to 130% of the conversion price on each trading day, and as a result, the holders have the option to convert all or any portion of their 2025 Notes through December 31, 2022. The 2025 Notes are classified as long-term debt. The Company recognized non-cash interest related to the amortization of transaction costs of $0.4 million and $1.1 million, all of which was capitalized, for the three and nine months ended September 30, 2022, respectively. The Company recorded $2.5 million and $7.6 million of accrued interest expense related to the principal amount for the three and nine months ended September 30, 2022, respectively, all of which was capitalized. Amended and Restated Credit Agreement, (the "Revolving Credit Facility") On September 1, 2022, the Company entered into the Revolving Credit Facility among the Company, Livent USA Corp (together with the Company, the “Borrowers”), certain subsidiaries of the Borrowers as guarantors, the lenders (the “Lenders”) and issuing banks and Citibank, N.A., as administrative agent. The Revolving Credit Facility amended and restated the Company’s Original Credit Agreement, as amended (the “Credit Agreement”). The Revolving Credit Facility provides for a $500 million senior secured revolving credit facility, $50 million of which is available for the issuance of letters of credit for the account of the Borrowers, with an option to request, and subject to each Lender’s sole discretion, that the aggregate revolving credit commitments be increased to up to $700 million. The issuance of letters of credit and the proceeds of revolving credit loans made pursuant to the Revolving Credit Facility may be used for general corporate purposes, including capital expenditures and permitted acquisitions. Revolving loans under the Revolving Credit Facility will bear interest at a floating rate, which will be (i) a base rate, (ii) Adjusted Term Secured Overnight Financing Rate (“SOFR”) (defined as the forward-looking SOFR term rate published by CME Group Benchmark Administration Limited plus 0.10% per annum subject to a floor of zero) or (iii) Euro Interbank Offered Rate (“EURIBOR”), plus, in each case, an applicable margin, as determined in accordance with the provisions of the Revolving Credit Facility. The Revolving Credit Facility includes a quarterly commitment fee on the average daily unused amount of each Lender’s revolving credit commitment at a rate equal to an applicable percentage based on the Company’s first lien leverage ratio. The initial commitment fee is 0.25% per annum. Amounts under the Revolving Credit Facility may be borrowed, repaid and re-borrowed from time to time until the final maturity date on September 1, 2027. Voluntary prepayments and commitment reductions are permitted at any time without payment of any prepayment fee upon proper notice and subject to minimum dollar amounts. The foregoing description of the Revolving Credit Facility does not purport to be complete and is qualified in its entirety by reference to the Amended and Restated Credit Agreement, which is filed as Exhibit 10.1 to this Quarterly Report on Form 10-Q. We recorded $2.2 million of incremental deferred financing costs in the condensed consolidated balance sheets for the Revolving Credit Facility commitment, arrangement and legal fees and a $0.1 million loss on debt extinguishment in the condensed consolidated statements of operations for the three and nine months ended September 30, 2022 for the write off of existing deferred financing costs to recognize a partial change in syndication related to the Revolving Credit Facility. The carrying value of our deferred financing costs was $3.0 million as of September 30, 2022. Covenants The Credit Agreement contains certain affirmative and negative covenants that are binding on us and our subsidiary, Livent USA Corp., as borrowers (the "Borrowers") and their subsidiaries, including, among others, restrictions (subject to exceptions and qualifications) on the ability of the Borrowers and their subsidiaries to create liens, to undertake fundamental changes, to incur debt, to sell or dispose of assets, to make investments, to make restricted payments such as dividends, distributions or equity repurchases, to change the nature of their businesses, to enter into transactions with affiliates and to enter into certain restrictive agreements. Furthermore, the Borrowers are subject to financial covenants regarding leverage (measured as the ratio of debt to adjusted earnings) and interest coverage (measured as the ratio of adjusted earnings to interest expense). Our financial covenants have not changed with the September 1, 2022 amendments to our Credit Agreement. Our maximum allowable first lien leverage ratio is 3.5 as of September 30, 2022. Our minimum allowable interest coverage ratio is 3.5. We were in compliance with all requirements of the covenants as of September 30, 2022.

Equity

Equity	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Equity	Equity As of September 30, 2022 and December 31, 2021, we had 2 billion shares of common stock authorized. The following is a summary of Livent's common stock issued and outstanding: Issued Treasury Outstanding Balance as of December 31, 2021 161,791,602 (101,618) 161,689,984 RSU awards 64,539 — 64,539 Stock option awards 120,688 — 120,688 Net purchases of treasury stock - NQSP — (1,460) (1,460) Issuance of common stock 17,500,000 — 17,500,000 Balance as of September 30, 2022 179,476,829 (103,078) 179,373,751 On June 6, 2022, the Company closed on the QLP Merger and issued 17,500,000 shares of its common stock, par value $0.001 per share, in a private placement as consideration to acquire the remaining 50% share of QLP previously owned by Pallinghurst and certain of its investors. See Note 6 for details. Accumulated other comprehensive loss Summarized below is the roll forward of accumulated other comprehensive loss, net of tax. (in Millions) Foreign currency adjustments Derivative Instruments (1) Total Accumulated other comprehensive loss, net of tax as of December 31, 2021 $ (43.1) $ 0.2 $ (42.9) Other comprehensive losses before reclassifications (11.5) — (11.5) Amounts reclassified from accumulated other comprehensive loss — 0.2 0.2 Accumulated other comprehensive loss, net of tax as of September 30, 2022 $ (54.6) $ 0.4 $ (54.2) (in Millions) Foreign currency adjustments Derivative Instruments (1) Total Accumulated other comprehensive loss, net of tax as of December 31, 2020 $ (44.4) $ — $ (44.4) Other comprehensive loss before reclassifications (0.2) — (0.2) Accumulated other comprehensive loss, net of tax as of September 30, 2021 $ (44.6) $ — $ (44.6) 1. See Note 12 for more information. Reclassifications of accumulated other comprehensive loss Hedging losses reclassified from accumulated other comprehensive loss for the three and nine months ended September 30, 2022 were $0.3 million and $0.2 million, respectively, net of provision for income taxes of less than $0.1 million for each period. No amounts were reclassified from accumulated other comprehensive loss the three and nine months ended September 30, 2021. Dividends

Earnings_(Loss) Per Share

Earnings/(Loss) Per Share	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Earnings/(Loss) Per Share	Earnings/(Loss) Per Share Earnings/(loss) per common share is computed by dividing net income/(loss) by the weighted average number of common shares outstanding during the period on a basic and diluted basis. Our potentially dilutive securities include potential common shares related to our stock options, restricted stock units, performance restricted stock units and 2025 Notes. See Note 12 to our consolidated financial statements in Part II, Item 8 of our 2021 Annual Report on Form 10-K for more information. Diluted earnings/(loss) per share (“Diluted EPS”) considers the impact of potentially dilutive securities except in periods in which there is a loss because the inclusion of the potential common shares would have an anti-dilutive effect. Diluted EPS excludes the impact of potential common shares related to our stock options in periods in which the option exercise price is greater than the average market price of our common stock for the period. We use the if-converted method when calculating the potential dilutive effect, if any, of our 2025 Notes. Earnings/(loss) applicable to common stock and common stock shares used in the calculation of basic and diluted earnings/(loss) per share are as follows: (in Millions, Except Share and Per Share Data) Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Numerator: Net income/(loss) (1) $ 77.6 $ (12.6) $ 190.8 $ (6.9) Denominator: Weighted average common shares outstanding - basic 179.3 161.6 169.3 152.3 Dilutive share equivalents from share-based plans 2.0 — 1.8 — Dilutive share equivalents from 2025 Notes 28.1 — 28.1 — Weighted average common shares outstanding - diluted 209.4 161.6 199.2 152.3 Basic earnings/(loss) per common share: Net income/(loss) per weighted average share - basic $ 0.43 $ (0.08) $ 1.13 $ (0.05) Diluted earnings/(loss) per common share: Net income/(loss) per weighted average share - diluted $ 0.37 $ (0.08) $ 0.96 $ (0.05) 1. For the three and nine months ended September 30, 2022 and for the three months ended September 30, 2021, all of the interest for the 2025 Notes was capitalized. The following table presents weighted average share equivalents associated with share-based plans and the 2025 Notes that were excluded from the diluted shares outstanding calculation because the result would have been antidilutive. See Note 11 to our consolidated financial statements in Part II, Item 8 of our 2021 Annual Report on Form 10-K for more information on the 2025 Notes. (in Millions) Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Share equivalents from share-based plans — 1.5 — 1.4 Share equivalents from 2025 Notes — 28.1 — 28.1 Total antidilutive weighted average share equivalents — 29.6 — 29.5 Anti-dilutive stock options

Financial Instruments, Risk Man

Financial Instruments, Risk Management and Fair Value Measurements	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Financial Instrument, Risk Management and Fair Value Measurements	Financial Instruments, Risk Management and Fair Value Measurements current assets, and trade payables approximates their fair value and are considered Level 1 investments. Our other financial instruments include the following: Financial Instrument Valuation Method Foreign exchange forward contracts Estimated amounts that would be received or paid to terminate the contracts at the reporting date based on current market prices for applicable currencies. The estimated fair value of our foreign exchange forward contracts have been determined using standard pricing models which take into account the present value of expected future cash flows discounted to the balance sheet date. These standard pricing models utilize inputs derived from, or corroborated by, observable market data such as interest rate yield curves and currency and commodity spot and forward rates. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The inputs used to measure fair value are classified into the following hierarchy: Level 1 - Unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 - Unadjusted quoted prices in active markets for similar assets or liabilities, or unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are observable for the asset or liability. Level 3 - Unobservable inputs for the asset or liability. The estimated fair value and the carrying amount of debt was $813.2 million and $259.3 million, respectively, as of September 30, 2022. Our 2025 Notes are classified as Level 2 in the fair value hierarchy. Use of Derivative Financial Instruments to Manage Risk We mitigate certain financial exposures connected to currency risk through a program of risk management that includes the use of derivative financial instruments. We enter into foreign exchange forward contracts to reduce the effects of fluctuating foreign currency exchange rates. We formally document all relationships between hedging instruments and hedged items, as well as the risk management objective and strategy for undertaking various hedge transactions. This process includes relating derivatives that are designated as fair value or cash flow hedges to specific assets and liabilities on the balance sheet or to specific firm commitments or forecasted transactions. We also assess both at the inception of the hedge and on an ongoing basis, whether each derivative is highly effective in offsetting changes in fair values or cash flows of the hedged item. If we determine that a derivative is not highly effective as a hedge, or if a derivative ceases to be a highly effective hedge, we discontinue hedge accounting with respect to that derivative prospectively. Foreign Currency Exchange Risk Management We conduct business in many foreign countries, exposing earnings, cash flows, and our financial position to foreign currency risks. The majority of these risks arise as a result of foreign currency transactions. The primary currencies for which we have exchange rate exposure are the Euro, the British pound, the Chinese yuan, the Argentine peso, and the Japanese yen. We currently do not hedge foreign currency risks associated with the Argentine peso due to the limited availability and the high cost of suitable derivative instruments. Our policy is to minimize exposure to adverse changes in currency exchange rates. This is accomplished through a controlled program of risk management that could include the use of foreign currency debt and forward foreign exchange contracts. We also use forward foreign exchange contracts to hedge firm and highly anticipated foreign currency cash flows, with an objective of balancing currency risk to provide adequate protection from significant fluctuations in the currency markets. Concentration of Credit Risk Our counterparties to derivative contracts are primarily major financial institutions. We limit the dollar amount of contracts entered into with any one financial institution and monitor counterparties’ credit ratings. We also enter into master netting agreements with each financial institution, where possible, which helps mitigate the credit risk associated with our financial instruments. While we may be exposed to credit losses due to the nonperformance of counterparties, we consider this risk remote. Accounting for Derivative Instruments and Hedging Activities Cash Flow Hedges We recognize all derivatives on the balance sheet at fair value. On the date we enter into the derivative instrument, we generally designate the derivative as a hedge of the variability of cash flows to be received or paid related to a forecasted transaction (cash flow hedge). We record in accumulated other comprehensive loss ("AOCL") changes in the fair value of derivatives that are designated as and meet all the required criteria for, a cash flow hedge. We then reclassify these amounts into earnings as the underlying hedged item affects earnings. In contrast we immediately record in earnings changes in the fair value of derivatives that are not designated as cash flow hedges. As of September 30, 2022, we had open foreign currency forward contracts in AOCL in a net after-tax gain position of $0.4 million designated as cash flow hedges of underlying forecasted sales and purchases. As of September 30, 2022 we had open forward contracts with various expiration dates to buy, sell or exchange foreign currencies with a U.S. dollar equivalent of approximately $32.0 million. A net after-tax gain of $0.4 million, representing open foreign currency exchange contracts, will be realized in earnings during the year ending December 31, 2022 if spot rates in the future are consistent with market rates as of September 30, 2022. The actual effect on earnings will be dependent on the actual spot rates when the forecasted transactions occur. We recognize derivative gains and losses in the “Costs of sales and services” line in the condensed consolidated statements of operations. Derivatives Not Designated As Cash Flow Hedging Instruments We hold certain forward contracts that have not been designated as cash flow hedging instruments for accounting purposes. Contracts used to hedge the exposure to foreign currency fluctuations associated with certain monetary assets and liabilities are not designated as cash flow hedging instruments and changes in the fair value of these items are recorded in earnings. We had open forward contracts not designated as cash flow hedging instruments for accounting purposes with various expiration dates to buy, sell or exchange foreign currencies with a U.S. dollar equivalent of approximately $50.0 million as of September 30, 2022. Fair Value of Derivative Instruments. The following tables provide the gross fair value and net balance sheet presentation of our derivative instruments. September 30, 2022 Gross Amount of Derivatives (in Millions) Designated as Cash Flow Hedges Derivative assets Foreign exchange contracts $ 1.1 Total derivative assets (1) 1.1 Derivative liabilities Foreign exchange contracts 0.6 Total derivative liabilities (2) 0.6 Net derivative assets $ 0.5 December 31, 2021 Gross Amount of Derivatives (in Millions) Designated as Cash Flow Hedges Derivatives Foreign exchange contracts $ 0.2 Total derivative assets (1) 0.2 Net derivative assets $ 0.2 ___________________ 1. Net balance is included in “Prepaid and other current assets” in the condensed consolidated balance sheets. 2. Net balance is included in “Accrued and other liabilities” in the condensed consolidated balance sheets. Derivatives in Cash Flow Hedging Relationships The following tables summarize the losses related to our cash flow hedges and derivatives not designated as cash flow hedging instruments. For the three months ended March 31, 2021, we did not have any open derivative cash flow hedge contracts. (in Millions) Total Foreign Exchange Contracts Accumulated other comprehensive income, net of tax as of December 31, 2021 $ 0.2 Unrealized hedging gains, net of tax 0.1 Total derivatives instruments impact on comprehensive income, net of tax 0.1 Accumulated other comprehensive income, net of tax as of March 31, 2022 $ 0.3 Reclassification of deferred hedging gains, net of tax (0.1) Total derivatives instruments impact on comprehensive income, net of tax (0.1) Accumulated other comprehensive income, net of tax at June 30, 2022 $ 0.2 Unrealized hedging losses, net of tax (0.1) Reclassification of deferred hedging losses, net of tax 0.3 Total derivatives instruments impact on comprehensive income, net of tax 0.2 Accumulated other comprehensive income, net of tax at September 30, 2022 $ 0.4 (in Millions) Total Foreign Exchange Contracts Accumulated other comprehensive income, net of tax as of March 31, 2021 $ — Unrealized hedging gains, net of tax 0.1 Total derivatives instruments impact on comprehensive income, net of tax 0.1 Accumulated other comprehensive income, net of tax at June 30, 2021 $ 0.1 Unrealized hedging losses, net of tax (0.1) Total derivatives instruments impact on comprehensive income, net of tax (0.1) Accumulated other comprehensive income, net of tax at September 30, 2021 $ — Derivatives Not Designated as Cash Flow Hedging Instruments Location of Loss Amount of Pre-tax Loss Recognized in Income on Derivatives (1) Three Months Ended September 30, Nine Months Ended September 30, (in Millions) 2022 2021 2022 2021 Foreign Exchange contracts Cost of sales (2) $ (0.6) $ (0.2) $ (4.5) $ (1.1) Total $ (0.6) $ (0.2) $ (4.5) $ (1.1) ____________________ 1. Amounts represent the gain or loss on the derivative instrument offset by the gain or loss on the hedged item. 2. A gain of $0.1 million and loss of less than $0.1 million related to intercompany loan hedges is included in Restructuring and other charges in the consolidated statement of operations for the three and nine months ended September 30, 2022, respectively. A loss of $0.1 million and $0.2 million related to intercompany loan hedges is included in Restructuring and other charges in the consolidated statement of operations for the three and nine months ended September 30, 2021, respectively. Fair Value Measurements Recurring Fair Value Measurements The following tables present our fair-value hierarchy for those assets and liabilities measured at fair-value on a recurring basis in our condensed consolidated balance sheets. (in Millions) September 30, 2022 Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Assets Investments in deferred compensation plan (1) $ 2.7 $ 2.7 $ — $ — Derivatives – Foreign exchange 1.1 — 1.1 — Total Assets $ 3.8 $ 2.7 $ 1.1 $ — Liabilities Deferred compensation plan obligation (2) $ 5.9 $ 5.9 $ — $ — Derivatives – Foreign exchange 0.6 — 0.6 — Total Liabilities $ 6.5 $ 5.9 $ 0.6 $ — (in Millions) December 31, 2021 Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Assets Investments in deferred compensation plan (1) $ 3.4 $ 3.4 $ — — Derivatives – Foreign exchange 0.2 — 0.2 — Total Assets $ 3.6 $ 3.4 $ 0.2 $ — Liabilities Deferred compensation plan obligation (2) $ 5.9 $ 5.9 $ — $ — Total Liabilities $ 5.9 $ 5.9 $ — $ — ____________________ 1. Balance is included in “Investments” in the condensed consolidated balance sheets. Livent NQSP investments in Livent common stock are recorded as "Treasury stock" in the condensed consolidated balance sheets and carried at historical cost. A mark-to-market loss of $0.8 million and $0.6 million was recorded for the three and nine months ended September 30, 2022, respectively, related to the Livent common stock. The mark-to-market losses were recorded in "Selling, general and administrative expense" in the condensed consolidated statement of operations, with a corresponding offset to the deferred compensation plan obligation in the condensed consolidated balance sheets. 2. Balance is included in “Other long-term liabilities” in the condensed consolidated balance sheets.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Contingencies We are a party to various legal proceedings, certain of these matters are discussed below. Livent records liabilities for estimated losses from contingencies when information available indicates that a loss is probable and the amount of the loss, or range of loss, can be reasonably estimated. As additional information becomes available, management adjusts its assessments and estimates. Legal costs are expensed as incurred. In addition to the legal proceedings noted below, we have certain contingent liabilities arising in the ordinary course of business. Some of these contingencies are known but are so preliminary that the merits cannot be determined, or if more advanced, are not deemed material based on current knowledge; and some are unknown - for example, claims with respect to which we have no notice or claims which may arise in the future from products sold, guarantees or warranties made, or indemnities provided. Therefore, we are unable to develop a reasonable estimate of our potential exposure of loss for these contingencies, either individually or in the aggregate, at this time. There can be no assurance that the outcome of these contingencies will be favorable, and adverse results in certain of these contingencies could have a material adverse effect on the consolidated financial position, results of operations in any one reporting period, or liquidity. Argentine Customs & Tax Authority Matters Minera del Altiplano SA, our subsidiary in Argentina (“MdA”), has received notices from the Argentine Customs Authorities that they are conducting customs audits in Salta (for 2016 to 2017 and 2018 to 2019), Rosario (for 2016 and 2017), Buenos Aires and Ezeiza (for 2018 and 2019) regarding the export of Lithium Carbonate by MdA from each of those locations. MdA was also notified from the Argentine Tax Authority of the start of transfer pricing audits for the periods 2017 and 2018. During a part of this period, MdA was a subsidiary of FMC. However, the Company agreed to bear any possible liability for these types of matters under the terms of the Tax Matters Agreement that it entered into with FMC in connection with the Separation. A range of reasonably possible liabilities, if any, cannot be currently estimated by the Company. Leases All of our leases are operating leases as of September 30, 2022 and December 31, 2021. We have operating leases for corporate offices, manufacturing facilities, and land. Our leases have remaining lease terms of one Three Months Ended September 30, Nine Months Ended September 30, (in Millions, except for weighted-average amounts) 2022 2021 2022 2021 Lease Cost Operating lease cost $ 0.3 $ 0.4 $ 1.0 $ 1.0 Short-term lease cost 0.1 0.3 0.3 1.0 Variable lease cost — — — 0.1 Total lease cost (1) $ 0.4 $ 0.7 $ 1.3 $ 2.1 Other information Cash paid for amounts included in the measurement of lease liabilities: Cash paid for operating leases $ 0.3 $ 0.5 $ 1.0 $ 1.6 __________________________ 1. Lease expense is classified as "Selling, general and administrative expenses" in our condensed consolidated statements of operations. As of September 30, 2022, our operating leases had a weighted average remaining lease term of 7.7 years and a weighted average discount rate of 4.9%. The table below presents a maturity analysis of our operating lease liabilities for each of the next five years and a total of the amounts for the remaining years. (in Millions) Undiscounted cash flows Remainder of 2022 $ 0.3 2023 1.1 2024 1.0 2025 1.1 2026 0.2 Thereafter 2.4 Total future minimum lease payments 6.1 Less: Imputed interest (1.0) Total $ 5.1

Supplemental Information

Supplemental Information	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Supplemental Information	Supplemental Information The following tables present details of prepaid and other current assets, other assets, accrued and other current liabilities, and other long-term liabilities as presented on the condensed consolidated balance sheets: (in Millions) September 30, 2022 December 31, 2021 Prepaid and other current assets Tax related items $ 19.0 $ 17.7 Prepaid expenses 6.9 12.2 Argentina government receivable (1) 6.3 13.3 Other receivables 7.1 2.3 Bank Acceptance Drafts (2) 8.7 — Derivative assets (Note 12) 1.1 0.2 Other current assets 7.4 9.6 Total $ 56.5 $ 55.3 (in Millions) September 30, 2022 December 31, 2021 Other assets Argentina government receivable (1) $ 76.6 $ 55.8 Advance to contract manufacturers (3) 16.3 16.0 Long-term raw materials inventory 1.6 4.9 Tax related items 3.8 1.3 Capitalized software, net 1.5 1.5 Other assets 12.1 11.4 Total $ 111.9 $ 90.9 _________________ 1. We conduct business in Argentina. As of September 30, 2022 and December 31, 2021, $39.3 million and $38.4 million, respectively, of outstanding receivables due from the Argentina government, which primarily represent export tax and export rebate receivables, was denominated in U.S. dollars. As with all outstanding receivable balances, we continually review recoverability by analyzing historical experience, current collection trends and regional business and political factors among other factors. 2. Bank Acceptance Drafts are a common Chinese finance note used to settle trade transactions. Livent accepts these notes from Chinese customers based on criteria intended to ensure collectability and limit working capital usage. 3. We record deferred charges for certain contract manufacturing agreements which we amortize over the term of the underlying contract. (in Millions) September 30, 2022 December 31, 2021 Accrued and other current liabilities Accrued investment in unconsolidated affiliate $ 16.6 $ 6.2 Accrued payroll 16.5 17.1 Plant restructuring reserves 3.0 3.2 Advance customer payments 7.3 — Retirement liability - 401k 2.0 2.5 Derivative liabilities (Note 12) 0.6 — Environmental reserves, current 0.5 0.5 Severance related 0.2 — Other accrued and other current liabilities (1) 22.2 32.3 Total $ 68.9 $ 61.8 (in Millions) September 30, 2022 December 31, 2021 Other long-term liabilities Deferred compensation plan obligation $ 5.9 $ 5.9 Contingencies related to uncertain tax positions (2) 6.1 2.3 Self-insurance reserves 1.7 1.5 Asset retirement obligations 0.3 0.3 Other long-term liabilities 2.7 1.7 Total $ 16.7 $ 11.7 ____________________ 1. Amounts p rimarily include accrued capital expenditures related to our expansion projects. 2. As of September 30, 2022, we have recorded a liability for uncertain tax positions of $5.7 million and a $0.4 million indem nification liability where the offsetting uncertain tax position is with FMC, per the tax matters agreement.

Recently Issued and Adopted A_2

Recently Issued and Adopted Accounting Pronouncements and Regulatory Items (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of Accounting	The accompanying condensed consolidated financial statements were prepared in accordance with the requirements of the Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules, certain notes or other financial information that are normally required by U.S. GAAP have been condensed or omitted from these interim financial statements.
New Accounting Guidance and Regulatory Items and Recently Adopted Accounting Guidance	Recently Issued and Adopted Accounting Pronouncements and Regulatory Items New accounting guidance and regulatory items In November 2021, the Financial Accounting Standard Board ("FASB") issued ASU No. 2021-10, Government Assistance (Topic 832) . This ASU requires business entities to disclose information about government assistance they receive if the transactions were accounted for by analogy to either a grant or a contribution accounting model. The disclosure requirements include the nature of the transaction and the related accounting policy used, the line items on the balance sheets and statements of operations that are affected and the amounts applicable to each financial statement line item and the significant terms and conditions of the transactions. The ASU is effective for annual periods beginning after December 15, 2021. The disclosure requirements can be applied either retrospectively or prospectively to all transactions in the scope of the amendments that are reflected in the financial statements at the date of initial application and new transactions that are entered into after the date of initial application. We are evaluating the impact of this ASU on our consolidated financial statements. In April 2020, FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848). T he amendments in this ASU provide optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. An entity may optionally elect to apply the amendments effective in the first interim period that includes or is subsequent to March 12, 2020 through December 31, 2022. We do not expect adoption to have material impact on our condensed consolidated financial statements.
Revenue Recognition	The balance of receivables from contracts with customers listed in the table above represents the current trade receivables, net of allowance for doubtful accounts. The allowance for receivables represents our best estimate of the probable losses associated with potential customer defaults. We determine the allowance based on historical experience, current collection trends, and external business factors such as economic factors, including regional bankruptcy rates, and political factors. Performance obligations

Principal Accounting Policies_2

Principal Accounting Policies and Related Financial Information (Tables)	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Share-Based Payment Award, PRSU Valuation Assumptions	As a result, the Monte Carlo model is applied and the most significant valuation assumptions used related to the 2022 PRSUs during the year ending December 31, 2022, include: Valuation date stock price $21.01 Expected volatility 72.99% Risk free rate 1.74%

Revenue Recognition (Tables)

Revenue Recognition (Tables)	9 Months Ended
	Sep. 30, 2022
Revenue from Contract with Customer [Abstract]
Schedule of Disaggregation of Revenue	The following table provides information about disaggregated revenue by major geographical region: (in Millions) Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 North America (1) (2) $ 46.8 $ 15.9 $ 109.3 $ 44.2 Latin America 0.7 — 1.8 — Europe, Middle East & Africa 30.1 14.2 76.8 46.0 Asia Pacific (1) (2) 154.0 73.5 405.9 207.3 Total Revenue $ 231.6 $ 103.6 $ 593.8 $ 297.5 1. During the three months ended September 30, 2022, countries with sales in excess of 10% of combined revenue consisted of Japan, the U.S., and China. Sales for the three months ended September 30, 2022 for Japan, the U.S., and China totaled $39.2 million, $45.1 million, $85.0 million, respectively. During the nine months ended September 30, 2022, countries with sales in excess of 10% of combined revenue consisted of Japan, the U.S., and China. Sales for the nine months ended September 30, 2022 for Japan, the U.S., and China totaled $124.1 million, $105.6 million, $208.8 million, respectively. During the three months ended September 30, 2021, countries with sales in excess of 10% of combined revenue consisted of Japan, the U.S. and China. Sales for the three months ended September 30, 2021 for Japan, the U.S. and China totaled $24.5 million, $15.6 million and $36.6 million, respectively. During the nine months ended September 30, 2021, countries with sales in exce ss of 10% of combined revenue consisted of Japan, South Korea, the U.S. and China . Sales for the nine months ended September 30, 2021 for Japan, South Korea, the U.S. and China totaled $65.1 million, $38.1 million, $43.5 million and $89.9 million, respectively . 2. In the fourth quarter of 2021, we reclassified certain revenue from the nine months ended September 30, 2021 from North America to Asia Pacific to present revenue based on product destination. The following table provides information about disaggregated revenue by major product category: (in Millions) Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Lithium Hydroxide $ 118.4 $ 50.7 $ 299.5 $ 160.5 Butyllithium 88.2 27.4 203.1 76.1 High Purity Lithium Metal and Other Specialty Compounds 11.9 9.8 42.0 27.6 Lithium Carbonate and Lithium Chloride 13.1 15.7 49.2 33.3 Total Revenue $ 231.6 $ 103.6 $ 593.8 $ 297.5
Schedule of Receivables and Contract Liabilities	The following table presents the opening and closing balances of our receivables, net of allowances and contract liabilities from contracts with customers. As o f December 31, 2021, there were no significant contract liabilities recorded in the condensed consolidated balance sheets. (in Millions) Balance as of September 30, 2022 Balance as of December 31, 2021 Increase Receivables from contracts with customers, net of allowances $ 164.0 $ 96.4 $ 67.6 Contract liability - long-term $ 198.0 $ — $ 198.0

Inventories, Net (Tables)

Inventories, Net (Tables)	9 Months Ended
	Sep. 30, 2022
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories consisted of the following: (in Millions) September 30, 2022 December 31, 2021 Finished goods $ 55.6 $ 52.2 Semi-finished goods 56.4 43.6 Raw materials, supplies, and other 29.8 38.8 Inventory, net $ 141.8 $ 134.6

Restructuring and Other Charg_2

Restructuring and Other Charges (Tables)	9 Months Ended
	Sep. 30, 2022
Restructuring and Related Activities [Abstract]
Schedule of Restructuring Charges and Asset Disposals	The following table shows other charges included in "Restructuring and other charges" in the condensed consolidated statements of operations: Three Months Ended September 30, Nine Months Ended September 30, (in Millions) 2022 2021 2022 2021 Restructuring charges: Severance-related and exit costs (1) $ 0.4 $ 0.1 $ 0.9 $ 0.2 Other charges: Environmental remediation (2) 0.1 0.1 0.3 0.3 Other (3) 0.2 0.9 3.4 2.9 Total Restructuring and other charges $ 0.7 $ 1.1 $ 4.6 $ 3.4 ___________________ 1. The three and nine months ended September 30, 2022 includes severance costs for management changes at certain administrative facilities. 2. There is one environmental remediation site in Bessemer City, North Carolina.

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Schedule of Long-term Debt	Long-term debt consists of the following: Interest Rate Percentage Maturity September 30, 2022 December 31, 2021 (in Millions) SOFR borrowings Base rate borrowings Revolving Credit Facility (1) 4.89% 7.0% 2027 $ — $ — Deferred Payment Note 8.0% 2022 13.5 — 4.125% Convertible Senior Notes due 2025 4.125% 2025 245.8 245.8 Transaction costs - 2025 Notes (4.2) (5.4) Subtotal long-term debt (including current maturities) 255.1 240.4 Less current maturities (13.5) — Total long-term debt $ 241.6 $ 240.4 ______________________________ 1. As of September 30, 2022 and December 31, 2021, there were $14.5 million in letters of credit outstanding under our Revolving Credit Facility and $485.5 million available funds as of September 30, 2022 and December 31, 2021. Fund availability is subject to the Company meeting its debt covenants.

Equity (Tables)

Equity (Tables)	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Schedule of Common Stock Issued and Outstanding	The following is a summary of Livent's common stock issued and outstanding: Issued Treasury Outstanding Balance as of December 31, 2021 161,791,602 (101,618) 161,689,984 RSU awards 64,539 — 64,539 Stock option awards 120,688 — 120,688 Net purchases of treasury stock - NQSP — (1,460) (1,460) Issuance of common stock 17,500,000 — 17,500,000 Balance as of September 30, 2022 179,476,829 (103,078) 179,373,751
Schedule of Accumulated Other Comprehensive Income (Loss)	Summarized below is the roll forward of accumulated other comprehensive loss, net of tax. (in Millions) Foreign currency adjustments Derivative Instruments (1) Total Accumulated other comprehensive loss, net of tax as of December 31, 2021 $ (43.1) $ 0.2 $ (42.9) Other comprehensive losses before reclassifications (11.5) — (11.5) Amounts reclassified from accumulated other comprehensive loss — 0.2 0.2 Accumulated other comprehensive loss, net of tax as of September 30, 2022 $ (54.6) $ 0.4 $ (54.2) (in Millions) Foreign currency adjustments Derivative Instruments (1) Total Accumulated other comprehensive loss, net of tax as of December 31, 2020 $ (44.4) $ — $ (44.4) Other comprehensive loss before reclassifications (0.2) — (0.2) Accumulated other comprehensive loss, net of tax as of September 30, 2021 $ (44.6) $ — $ (44.6) 1. See Note 12 for more information.

Earnings_(Loss) Per Share (Tabl

Earnings/(Loss) Per Share (Tables)	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Schedule of Calculation of Basic and Diluted Earnings/(Loss) Per Share	Earnings/(loss) applicable to common stock and common stock shares used in the calculation of basic and diluted earnings/(loss) per share are as follows: (in Millions, Except Share and Per Share Data) Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Numerator: Net income/(loss) (1) $ 77.6 $ (12.6) $ 190.8 $ (6.9) Denominator: Weighted average common shares outstanding - basic 179.3 161.6 169.3 152.3 Dilutive share equivalents from share-based plans 2.0 — 1.8 — Dilutive share equivalents from 2025 Notes 28.1 — 28.1 — Weighted average common shares outstanding - diluted 209.4 161.6 199.2 152.3 Basic earnings/(loss) per common share: Net income/(loss) per weighted average share - basic $ 0.43 $ (0.08) $ 1.13 $ (0.05) Diluted earnings/(loss) per common share: Net income/(loss) per weighted average share - diluted $ 0.37 $ (0.08) $ 0.96 $ (0.05)
Schedule of Weighted Average Share Equivalents Associated with Share-Based Plans and the 2025 Notes	The following table presents weighted average share equivalents associated with share-based plans and the 2025 Notes that were excluded from the diluted shares outstanding calculation because the result would have been antidilutive. See Note 11 to our consolidated financial statements in Part II, Item 8 of our 2021 Annual Report on Form 10-K for more information on the 2025 Notes. (in Millions) Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Share equivalents from share-based plans — 1.5 — 1.4 Share equivalents from 2025 Notes — 28.1 — 28.1 Total antidilutive weighted average share equivalents — 29.6 — 29.5

Financial Instruments, Risk M_2

Financial Instruments, Risk Management and Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Schedule Of Financial Instrument Valuation Methods	Our other financial instruments include the following: Financial Instrument Valuation Method Foreign exchange forward contracts Estimated amounts that would be received or paid to terminate the contracts at the reporting date based on current market prices for applicable currencies.
Schedule of Derivative Assets at Fair Value	The following tables provide the gross fair value and net balance sheet presentation of our derivative instruments. September 30, 2022 Gross Amount of Derivatives (in Millions) Designated as Cash Flow Hedges Derivative assets Foreign exchange contracts $ 1.1 Total derivative assets (1) 1.1 Derivative liabilities Foreign exchange contracts 0.6 Total derivative liabilities (2) 0.6 Net derivative assets $ 0.5 December 31, 2021 Gross Amount of Derivatives (in Millions) Designated as Cash Flow Hedges Derivatives Foreign exchange contracts $ 0.2 Total derivative assets (1) 0.2 Net derivative assets $ 0.2 ___________________ 1. Net balance is included in “Prepaid and other current assets” in the condensed consolidated balance sheets. 2. Net balance is included in “Accrued and other liabilities” in the condensed consolidated balance sheets.
Schedule of Derivatives in Cash Flow Hedging Relationships	The following tables summarize the losses related to our cash flow hedges and derivatives not designated as cash flow hedging instruments. For the three months ended March 31, 2021, we did not have any open derivative cash flow hedge contracts. (in Millions) Total Foreign Exchange Contracts Accumulated other comprehensive income, net of tax as of December 31, 2021 $ 0.2 Unrealized hedging gains, net of tax 0.1 Total derivatives instruments impact on comprehensive income, net of tax 0.1 Accumulated other comprehensive income, net of tax as of March 31, 2022 $ 0.3 Reclassification of deferred hedging gains, net of tax (0.1) Total derivatives instruments impact on comprehensive income, net of tax (0.1) Accumulated other comprehensive income, net of tax at June 30, 2022 $ 0.2 Unrealized hedging losses, net of tax (0.1) Reclassification of deferred hedging losses, net of tax 0.3 Total derivatives instruments impact on comprehensive income, net of tax 0.2 Accumulated other comprehensive income, net of tax at September 30, 2022 $ 0.4 (in Millions) Total Foreign Exchange Contracts Accumulated other comprehensive income, net of tax as of March 31, 2021 $ — Unrealized hedging gains, net of tax 0.1 Total derivatives instruments impact on comprehensive income, net of tax 0.1 Accumulated other comprehensive income, net of tax at June 30, 2021 $ 0.1 Unrealized hedging losses, net of tax (0.1) Total derivatives instruments impact on comprehensive income, net of tax (0.1) Accumulated other comprehensive income, net of tax at September 30, 2021 $ —
Schedule of Derivatives Not Designated as Hedging Instruments	Location of Loss Amount of Pre-tax Loss Recognized in Income on Derivatives (1) Three Months Ended September 30, Nine Months Ended September 30, (in Millions) 2022 2021 2022 2021 Foreign Exchange contracts Cost of sales (2) $ (0.6) $ (0.2) $ (4.5) $ (1.1) Total $ (0.6) $ (0.2) $ (4.5) $ (1.1) ____________________ 1. Amounts represent the gain or loss on the derivative instrument offset by the gain or loss on the hedged item. 2. A gain of $0.1 million and loss of less than $0.1 million related to intercompany loan hedges is included in Restructuring and other charges in the consolidated statement of operations for the three and nine months ended September 30, 2022, respectively. A loss of $0.1 million and $0.2 million related to intercompany loan hedges is included in Restructuring and other charges in the consolidated statement of operations for the three and nine months ended September 30, 2021, respectively.
Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis	The following tables present our fair-value hierarchy for those assets and liabilities measured at fair-value on a recurring basis in our condensed consolidated balance sheets. (in Millions) September 30, 2022 Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Assets Investments in deferred compensation plan (1) $ 2.7 $ 2.7 $ — $ — Derivatives – Foreign exchange 1.1 — 1.1 — Total Assets $ 3.8 $ 2.7 $ 1.1 $ — Liabilities Deferred compensation plan obligation (2) $ 5.9 $ 5.9 $ — $ — Derivatives – Foreign exchange 0.6 — 0.6 — Total Liabilities $ 6.5 $ 5.9 $ 0.6 $ — (in Millions) December 31, 2021 Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Assets Investments in deferred compensation plan (1) $ 3.4 $ 3.4 $ — — Derivatives – Foreign exchange 0.2 — 0.2 — Total Assets $ 3.6 $ 3.4 $ 0.2 $ — Liabilities Deferred compensation plan obligation (2) $ 5.9 $ 5.9 $ — $ — Total Liabilities $ 5.9 $ 5.9 $ — $ — ____________________ 1. Balance is included in “Investments” in the condensed consolidated balance sheets. Livent NQSP investments in Livent common stock are recorded as "Treasury stock" in the condensed consolidated balance sheets and carried at historical cost. A mark-to-market loss of $0.8 million and $0.6 million was recorded for the three and nine months ended September 30, 2022, respectively, related to the Livent common stock. The mark-to-market losses were recorded in "Selling, general and administrative expense" in the condensed consolidated statement of operations, with a corresponding offset to the deferred compensation plan obligation in the condensed consolidated balance sheets. 2. Balance is included in “Other long-term liabilities” in the condensed consolidated balance sheets.

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Schedule of Lease Cost and Terms	Quantitative disclosures about our leases are summarized in the table below. Three Months Ended September 30, Nine Months Ended September 30, (in Millions, except for weighted-average amounts) 2022 2021 2022 2021 Lease Cost Operating lease cost $ 0.3 $ 0.4 $ 1.0 $ 1.0 Short-term lease cost 0.1 0.3 0.3 1.0 Variable lease cost — — — 0.1 Total lease cost (1) $ 0.4 $ 0.7 $ 1.3 $ 2.1 Other information Cash paid for amounts included in the measurement of lease liabilities: Cash paid for operating leases $ 0.3 $ 0.5 $ 1.0 $ 1.6 __________________________ 1. Lease expense is classified as "Selling, general and administrative expenses" in our condensed consolidated statements of operations.
Schedule of Maturity of Operating Lease Liabilities	The table below presents a maturity analysis of our operating lease liabilities for each of the next five years and a total of the amounts for the remaining years. (in Millions) Undiscounted cash flows Remainder of 2022 $ 0.3 2023 1.1 2024 1.0 2025 1.1 2026 0.2 Thereafter 2.4 Total future minimum lease payments 6.1 Less: Imputed interest (1.0) Total $ 5.1

Supplemental Information (Table

Supplemental Information (Tables)	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Prepaid and Other Assets	The following tables present details of prepaid and other current assets, other assets, accrued and other current liabilities, and other long-term liabilities as presented on the condensed consolidated balance sheets: (in Millions) September 30, 2022 December 31, 2021 Prepaid and other current assets Tax related items $ 19.0 $ 17.7 Prepaid expenses 6.9 12.2 Argentina government receivable (1) 6.3 13.3 Other receivables 7.1 2.3 Bank Acceptance Drafts (2) 8.7 — Derivative assets (Note 12) 1.1 0.2 Other current assets 7.4 9.6 Total $ 56.5 $ 55.3 (in Millions) September 30, 2022 December 31, 2021 Other assets Argentina government receivable (1) $ 76.6 $ 55.8 Advance to contract manufacturers (3) 16.3 16.0 Long-term raw materials inventory 1.6 4.9 Tax related items 3.8 1.3 Capitalized software, net 1.5 1.5 Other assets 12.1 11.4 Total $ 111.9 $ 90.9 _________________ 1. We conduct business in Argentina. As of September 30, 2022 and December 31, 2021, $39.3 million and $38.4 million, respectively, of outstanding receivables due from the Argentina government, which primarily represent export tax and export rebate receivables, was denominated in U.S. dollars. As with all outstanding receivable balances, we continually review recoverability by analyzing historical experience, current collection trends and regional business and political factors among other factors. 2. Bank Acceptance Drafts are a common Chinese finance note used to settle trade transactions. Livent accepts these notes from Chinese customers based on criteria intended to ensure collectability and limit working capital usage. 3. We record deferred charges for certain contract manufacturing agreements which we amortize over the term of the underlying contract.
Schedule of Accrued and Other Liabilities	(in Millions) September 30, 2022 December 31, 2021 Accrued and other current liabilities Accrued investment in unconsolidated affiliate $ 16.6 $ 6.2 Accrued payroll 16.5 17.1 Plant restructuring reserves 3.0 3.2 Advance customer payments 7.3 — Retirement liability - 401k 2.0 2.5 Derivative liabilities (Note 12) 0.6 — Environmental reserves, current 0.5 0.5 Severance related 0.2 — Other accrued and other current liabilities (1) 22.2 32.3 Total $ 68.9 $ 61.8 (in Millions) September 30, 2022 December 31, 2021 Other long-term liabilities Deferred compensation plan obligation $ 5.9 $ 5.9 Contingencies related to uncertain tax positions (2) 6.1 2.3 Self-insurance reserves 1.7 1.5 Asset retirement obligations 0.3 0.3 Other long-term liabilities 2.7 1.7 Total $ 16.7 $ 11.7 ____________________ 1. Amounts p rimarily include accrued capital expenditures related to our expansion projects. 2. As of September 30, 2022, we have recorded a liability for uncertain tax positions of $5.7 million and a $0.4 million indem nification liability where the offsetting uncertain tax position is with FMC, per the tax matters agreement.

Principal Accounting Policies_3

Principal Accounting Policies and Related Financial Information - Narrative (Details) - USD ($) $ / shares in Units, shares in Thousands		3 Months Ended		9 Months Ended
	Feb. 23, 2022	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Other gain		$ 0	$ 0	$ 22,200,000	$ 0
Performance Shares
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Awards granted (in shares)	63
Performance period (in years)	3 years
Awards granted, weighted average grant date fair value (USD per share)	$ 20.82
Performance Shares | Minimum
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Vesting percentage	0%
Performance Shares | Maximum
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Vesting percentage	200%

Principal Accounting Policies_4

Principal Accounting Policies and Related Financial Information - Fair Value Assumptions (Details) - Performance Shares	9 Months Ended
	Sep. 30, 2022 $ / shares
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Share price (USD per share)	$ 21.01
Expected volatility	72.99%
Risk free rate	1.74%

Revenue Recognition - Disaggreg

Revenue Recognition - Disaggregation of Revenue by Major Geographical Region (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Disaggregation of Revenue [Line Items]
Total Revenue	$ 231.6	$ 103.6	$ 593.8	$ 297.5
North America
Disaggregation of Revenue [Line Items]
Total Revenue	46.8	15.9	109.3	44.2
Latin America
Disaggregation of Revenue [Line Items]
Total Revenue	0.7	0	1.8	0
Europe, Middle East & Africa
Disaggregation of Revenue [Line Items]
Total Revenue	30.1	14.2	76.8	46
Asia Pacific
Disaggregation of Revenue [Line Items]
Total Revenue	154	73.5	405.9	207.3
Japan
Disaggregation of Revenue [Line Items]
Total Revenue	39.2	24.5	124.1	65.1
United States
Disaggregation of Revenue [Line Items]
Total Revenue	45.1	15.6	105.6	43.5
China
Disaggregation of Revenue [Line Items]
Total Revenue	$ 85	$ 36.6	$ 208.8	89.9
South Korea
Disaggregation of Revenue [Line Items]
Total Revenue				$ 38.1

Revenue Recognition - Narrative

Revenue Recognition - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Contract liability - long-term	$ 198		$ 198		$ 0
Customer One | Revenue from Contract with Customer Benchmark | Customer Concentration Risk
Disaggregation of Revenue [Line Items]
Concentration risk percentage	22%	35%	23%	36%
Ten Largest Customers | Revenue from Contract with Customer Benchmark | Customer Concentration Risk
Disaggregation of Revenue [Line Items]
Concentration risk percentage	62%	69%	61%	68%

Revenue Recognition - Disaggr_2

Revenue Recognition - Disaggregation of Revenue By Major Product Category (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Disaggregation of Revenue [Line Items]
Total Revenue	$ 231.6	$ 103.6	$ 593.8	$ 297.5
Lithium Hydroxide
Disaggregation of Revenue [Line Items]
Total Revenue	118.4	50.7	299.5	160.5
Butyllithium
Disaggregation of Revenue [Line Items]
Total Revenue	88.2	27.4	203.1	76.1
High Purity Lithium Metal and Other Specialty Compounds
Disaggregation of Revenue [Line Items]
Total Revenue	11.9	9.8	42	27.6
Lithium Carbonate and Lithium Chloride
Disaggregation of Revenue [Line Items]
Total Revenue	$ 13.1	$ 15.7	$ 49.2	$ 33.3

Revenue Recognition - Contract

Revenue Recognition - Contract Assets and Liabilities (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Receivables from contracts with customers, net of allowances	$ 164		$ 96.4
Increase	67.6
Contract liability - long-term	198		$ 0
Increase	$ 198	$ 0

Revenue Recognition - Performan

Revenue Recognition - Performance Obligations (Details) - USD ($) $ in Millions	Sep. 30, 2022	Jul. 25, 2022	Dec. 31, 2021
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Advance customer payments	$ 7.3		$ 0
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation	$ 713
Expected timing of satisfaction of performance obligations	3 years
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Expected timing of satisfaction of performance obligations		6 years

Inventories, Net - Schedule of

Inventories, Net - Schedule of Inventory (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Finished goods	$ 55.6	$ 52.2
Semi-finished goods	56.4	43.6
Raw materials, supplies, and other	29.8	38.8
Inventory, net	$ 141.8	$ 134.6

Investments (Details)

Investments (Details) - USD ($) $ in Millions		3 Months Ended			9 Months Ended
	Jun. 06, 2022	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Schedule of Equity Method Investments [Line Items]
Issuance of common stock - QLP Merger			$ 373.9
Equity in net loss of unconsolidated affiliate		$ 3.5		$ 1	$ 8.4	$ 3.7
Capital In Excess of Par
Schedule of Equity Method Investments [Line Items]
Issuance of common stock - QLP Merger	$ 373.9		$ 373.9
QLP
Schedule of Equity Method Investments [Line Items]
Number of shares issued in transaction (in shares)	17,500,000
Voting interest acquired (as a percent)	50%
Cash and cash equivalents	$ 0.3
Short-term debt	$ 13.5
QLP
Schedule of Equity Method Investments [Line Items]
Equity interest percentage	50%
Equity method investments	$ 387.1
Nemaska Lithium Inc.
Schedule of Equity Method Investments [Line Items]
Equity interest percentage	50%	50%			50%		25%
Equity method investments		$ 431.2			$ 431.2		$ 23.8
Equity in net loss of unconsolidated affiliate		$ 3.5			$ 8.4

Restructuring and Other Charg_3

Restructuring and Other Charges - Restructuring Charges in Consolidated Income (Details) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) site	Sep. 30, 2021 USD ($)
Restructuring charges:
Severance-related and exit costs	$ 0.4	$ 0.1	$ 0.9	$ 0.2
Other charges:
Environmental remediation	0.1	0.1	0.3	0.3
Other	0.2	0.9	3.4	2.9
Total Restructuring and other charges	$ 0.7	$ 1.1	$ 4.6	$ 3.4
Number of environmental remediation sites | site			1

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Income tax expense	$ 21.5	$ 15.4	$ 56.4	$ 13.8
Effective tax rate	21.70%	540.50%	22.80%	198.70%

Debt - Long-term Debt (Details)

Debt - Long-term Debt (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021	Nov. 26, 2020
Debt Instrument [Line Items]
Transaction costs - 2025 Notes	$ (4.2)	$ (5.4)
Subtotal long-term debt (including current maturities)	255.1	240.4
Less current maturities	(13.5)	0
Total long-term debt	241.6	240.4
Deferrable Notes
Debt Instrument [Line Items]
Long-Term debt, gross	$ 13.5	0
Convertible debt, interest rate	8%		8%
Convertible Debt
Debt Instrument [Line Items]
Long-Term debt, gross	$ 245.8	245.8
Convertible debt, interest rate	4.125%
Revolving Credit Facility
Debt Instrument [Line Items]
Letters of credit outstanding amount	$ 14.5	14.5
Line of credit, remaining borrowing capacity	485.5	485.5
Revolving Credit Facility | Line of Credit
Debt Instrument [Line Items]
Long-Term debt, gross	$ 0	$ 0
Secured Overnight Financing Rate (SOFR) | Revolving Credit Facility
Debt Instrument [Line Items]
Interest Rate Percentage	4.89%
Base rate borrowings | Revolving Credit Facility
Debt Instrument [Line Items]
Interest Rate Percentage	7%

Debt - Narrative (Details)

Debt - Narrative (Details)			3 Months Ended		9 Months Ended
	Oct. 14, 2022 USD ($)	Sep. 01, 2022 USD ($)	Sep. 30, 2022 USD ($) day	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Nov. 26, 2020 USD ($)
Debt Instrument [Line Items]
Loss on debt extinguishment			$ (100,000)	$ 0	$ (100,000)	$ 0
QLP | Nemaska Project
Debt Instrument [Line Items]
Equity interest percentage							50%
Deferrable Notes
Debt Instrument [Line Items]
Debt interest rate			8%		8%		8%
Deferrable Notes | QLP
Debt Instrument [Line Items]
Aggregate principal amount of debt							$ 12,500,000
Deferrable Notes | QLP | Subsequent Event
Debt Instrument [Line Items]
Prepayment cost	$ 13,500,000
Convertible Debt
Debt Instrument [Line Items]
Debt interest rate			4.125%		4.125%
Convertible Debt | 2025 Notes
Debt Instrument [Line Items]
Amortization of debt discount and transaction costs			$ 400,000		$ 1,100,000
Interest expense on debt, excluding amortization of debt discount			$ 2,500,000		7,600,000
Convertible Debt | Conversion Circumstance One
Debt Instrument [Line Items]
Threshold trading days | day			20
Threshold consecutive trading days | day			30
Threshold percentage of stock price trigger			130%
Line of Credit | Credit Agreement | Revolving Credit Facility
Debt Instrument [Line Items]
Credit facility borrowing capacity		$ 500,000,000
Line of credit facility, accordion feature, increase limit		$ 700,000,000
Debt instrument, floor rate		0%
Initial commitment fee		0.25%
Incremental deferred financing costs			$ 2,200,000		2,200,000
Loss on debt extinguishment			(100,000)		(100,000)
Deferred financing costs			$ 3,000,000		$ 3,000,000
Maximum net leverage ratio					3.5
Minimum allowable interest coverage ratio					3.5
Line of Credit | Credit Agreement | Revolving Credit Facility | Secured Overnight Financing Rate (SOFR)
Debt Instrument [Line Items]
Basis spread on variable rate		0.10%
Line of Credit | Credit Agreement | Letter of Credit
Debt Instrument [Line Items]
Credit facility borrowing capacity		$ 50,000,000

Equity - Additional Information

Equity - Additional Information (Details) - USD ($)		3 Months Ended			9 Months Ended
	Jun. 06, 2022	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Mar. 31, 2022	Dec. 31, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020
Class of Stock [Line Items]
Common stock, shares authorized (in shares)		2,000,000,000			2,000,000,000			2,000,000,000
Common stock, par value (in dollars per share)		$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001
Reclassification of deferred hedging gains, net of income tax		$ (300,000)	$ 100,000	$ 0	$ (200,000)	$ 0
Reclassification of deferred hedging losses included in net income, tax		$ (100,000)		$ 0	(100,000)	0
Dividends paid					$ 0	$ 0
QLP
Class of Stock [Line Items]
Number of shares issued in transaction (in shares)	17,500,000
Common stock, par value (in dollars per share)	$ 0.001
Voting interest acquired (as a percent)	50%

Equity - Summary of Common Stoc

Equity - Summary of Common Stock Activity (Details)	9 Months Ended
	Sep. 30, 2022 shares
Issued
Beginning balance (in shares)	161,791,602
Ending balance (in shares)	179,476,829
Treasury
Beginning balance (in shares)	(101,618)
Net purchases of Treasury Stock - deferred compensation plan (in shares)	(1,460)
Ending balance (in shares)	(103,078)
Outstanding
Beginning balance, outstanding (in shares)	161,689,984
Net purchases of Treasury Stock - deferred compensation plan (in shares)	(1,460)
Ending balance, outstanding (in shares)	179,373,751
Common stock
Issued
Stock issued during period (in shares)	17,500,000
Outstanding
Stock issued during period (in shares)	17,500,000
Livent Plan | Restricted Stock Units (RSUs)
Issued
Stock issued during period (in shares)	64,539
Outstanding
Stock issued during period (in shares)	64,539
Livent Plan | Stock Option
Issued
Stock issued during period (in shares)	120,688
Outstanding
Stock issued during period (in shares)	120,688

Equity - Schedule of Accumulate

Equity - Schedule of Accumulated Other Comprehensive Loss) (Details) - USD ($)	3 Months Ended					9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	$ 1,280,100,000	$ 849,000,000	$ 795,400,000	$ 797,100,000	$ 535,600,000	$ 795,400,000	$ 536,200,000
Other comprehensive losses before reclassifications						(11,500,000)	(200,000)
Reclassification of deferred losses included in net income/(loss), net of tax of $(0.1), zero, $(0.1) and zero	(300,000)	100,000		0		(200,000)	0
Reclassification of deferred hedging gain (losses), net of tax						200,000
Ending balance	1,354,600,000	1,280,100,000	849,000,000	784,500,000	797,100,000	1,354,600,000	784,500,000
Total
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(48,300,000)	(43,800,000)	(42,900,000)	(43,400,000)	(44,700,000)	(42,900,000)	(44,400,000)
Reclassification of deferred losses included in net income/(loss), net of tax of $(0.1), zero, $(0.1) and zero	(300,000)	100,000
Ending balance	(54,200,000)	(48,300,000)	(43,800,000)	(44,600,000)	(43,400,000)	(54,200,000)	(44,600,000)
Foreign currency adjustments
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance			(43,100,000)			(43,100,000)	(44,400,000)
Other comprehensive losses before reclassifications						(11,500,000)	(200,000)
Reclassification of deferred hedging gain (losses), net of tax						0
Ending balance	(54,600,000)			(44,600,000)		(54,600,000)	(44,600,000)
Derivative Instruments
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	200,000	300,000	200,000	100,000	0	200,000	0
Other comprehensive losses before reclassifications	(100,000)		100,000	(100,000)	100,000	0	0
Reclassification of deferred losses included in net income/(loss), net of tax of $(0.1), zero, $(0.1) and zero				200,000
Reclassification of deferred hedging gain (losses), net of tax	300,000	(100,000)
Ending balance	$ 400,000	$ 200,000	$ 300,000	$ 0	$ 100,000	$ 400,000	$ 0

Earnings_(Loss) Per Share - EPS

Earnings/(Loss) Per Share - EPS Calculation (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Numerator:
Net income/(loss), basic	$ 77.6	$ (12.6)	$ 190.8	$ (6.9)
Net income/(loss), diluted	$ 77.6	$ (12.6)	$ 190.8	$ (6.9)
Denominator:
Weighted average common shares outstanding - basic (in shares)	179.3	161.6	169.3	152.3
Dilutive share equivalents from share-based plans (in shares)	2	0	1.8	0
Dilutive share equivalents from 2025 Notes (in shares)	28.1	0	28.1	0
Weighted average common shares outstanding - diluted (in shares)	209.4	161.6	199.2	152.3
Basic earnings/(loss) per common share:
Net income/(loss) per weighted average share - basic (in shares)	$ 0.43	$ (0.08)	$ 1.13	$ (0.05)
Diluted earnings/(loss) per common share:
Net income/(loss) per weighted average share - diluted (in dollars per share)	$ 0.37	$ (0.08)	$ 0.96	$ (0.05)

Earnings_(Loss) Per Share - Wei

Earnings/(Loss) Per Share - Weighted Average Share Equivalents (Details) - shares shares in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share
Antidilutive securities (in shares)	0	29.6	0	29.5
Share equivalents from share-based plans
Antidilutive Securities Excluded from Computation of Earnings Per Share
Antidilutive securities (in shares)	0	1.5	0	1.4
Share equivalents from 2025 Notes
Antidilutive Securities Excluded from Computation of Earnings Per Share
Antidilutive securities (in shares)	0	28.1	0	28.1

Earnings_(Loss) Per Share - Nar

Earnings/(Loss) Per Share - Narrative (Details) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share
Antidilutive securities (in shares)	0	29,600,000	0	29,500,000
Stock Option
Antidilutive Securities Excluded from Computation of Earnings Per Share
Antidilutive securities (in shares)	0	0	0	542,760
Options granted, weighted average exercise price (in dollars per share)				$ 20.35

Financial Instruments, Risk M_3

Financial Instruments, Risk Management and Fair Value Measurements - Narrative (Details) $ in Millions	Sep. 30, 2022 USD ($)
Derivative [Line Items]
Open foreign currency forward contracts designated as cash flow hedges, U.S. dollar equivalent	$ 32
Forward Contracts
Derivative [Line Items]
AOCI, net	0.4
Foreign Exchange contracts | Not Designated as Hedging Instrument
Derivative [Line Items]
Open foreign currency forward contracts designated as cash flow hedges, U.S. dollar equivalent	50
Estimate of Fair Value Measurement
Derivative [Line Items]
Long-term debt value	813.2
Reported Value Measurement
Derivative [Line Items]
Long-term debt value	$ 259.3

Financial Instruments, Risk M_4

Financial Instruments, Risk Management and Fair Value Measurements - Schedule of Derivatives (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Total derivative assets	$ 1.1	$ 0.2
Total derivative liabilities	0.6
Net derivative assets	0.5	0.2
Foreign Exchange contracts
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Total derivative assets	1.1	$ 0.2
Total derivative liabilities	$ 0.6

Financial Instruments, Risk M_5

Financial Instruments, Risk Management and Fair Value Measurements - Derivatives in Cash Flow Hedging Relationships (Details) - USD ($) $ in Millions	3 Months Ended					9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	$ 1,280.1	$ 849	$ 795.4	$ 797.1	$ 535.6	$ 795.4	$ 536.2
Unrealized hedging gains, net of tax						(11.5)	(0.2)
Reclassification of deferred hedging gain (losses), net of tax						0.2
Total derivatives instruments impact on comprehensive income, net of tax	(5.9)			(1.2)		(11.3)	(0.2)
Ending balance	1,354.6	1,280.1	849	784.5	797.1	1,354.6	784.5
Derivative Instruments
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	0.2	0.3	0.2	0.1	0	0.2	0
Unrealized hedging gains, net of tax	(0.1)		0.1	(0.1)	0.1	0	0
Reclassification of deferred hedging gain (losses), net of tax	0.3	(0.1)
Total derivatives instruments impact on comprehensive income, net of tax	0.2	(0.1)	0.1	(0.1)	0.1
Ending balance	$ 0.4	$ 0.2	$ 0.3	$ 0	$ 0.1	$ 0.4	$ 0

Financial Instruments, Risk M_6

Financial Instruments, Risk Management and Fair Value Measurements - Derivatives Not Designated As Cash Flow Hedging Instruments (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Derivative [Line Items]
Amount of pre-tax gain or (loss) recognized in income on derivatives	$ (0.6)	$ (0.2)	$ (4.5)	$ (1.1)
Foreign Exchange contracts
Derivative [Line Items]
Amount of pre-tax gain or (loss) recognized in income on derivatives	(0.6)	(0.2)	(4.5)	(1.1)
Foreign Exchange contracts | Subsidiaries
Derivative [Line Items]
Amount of pre-tax gain or (loss) recognized in income on derivatives	$ 0.1	$ 0.1	$ 0.1	$ 0.2

Financial Instruments, Risk M_7

Financial Instruments, Risk Management and Fair Value Measurements - Recurring Fair Value Measurements (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022	Dec. 31, 2021
Assets
Investments in deferred compensation plan	$ 2.7	$ 2.7	$ 3.4
Derivatives – Foreign exchange	1.1	1.1	0.2
Total Assets	3.8	3.8	3.6
Liabilities
Deferred compensation plan obligation	5.9	5.9	5.9
Derivatives – Foreign exchange	0.6	0.6
Total Liabilities	6.5	6.5	5.9
Selling, General and Administrative Expenses
Liabilities
Mark-to-market gain on common stock	0.8	0.6
Quoted Prices in Active Markets for Identical Assets (Level 1)
Assets
Investments in deferred compensation plan	2.7	2.7	3.4
Derivatives – Foreign exchange	0	0	0
Total Assets	2.7	2.7	3.4
Liabilities
Deferred compensation plan obligation	5.9	5.9	5.9
Derivatives – Foreign exchange	0	0
Total Liabilities	5.9	5.9	5.9
Significant Other Observable Inputs (Level 2)
Assets
Investments in deferred compensation plan	0	0	0
Derivatives – Foreign exchange	1.1	1.1	0.2
Total Assets	1.1	1.1	0.2
Liabilities
Deferred compensation plan obligation	0	0	0
Derivatives – Foreign exchange	0.6	0.6
Total Liabilities	0.6	0.6	0
Significant Unobservable Inputs (Level 3)
Assets
Investments in deferred compensation plan	0	0	0
Derivatives – Foreign exchange	0	0	0
Total Assets	0	0	0
Liabilities
Deferred compensation plan obligation	0	0	0
Derivatives – Foreign exchange	0	0
Total Liabilities	$ 0	$ 0	$ 0

Commitments and Contingencies -

Commitments and Contingencies - Narrative (Details)	Sep. 30, 2022
Lessee, Lease, Description [Line Items]
Operating lease, weighted average remaining lease term (in years)	7 years 8 months 12 days
Operating lease, weighted average discount rate (as a percent)	4.90%
Minimum
Lessee, Lease, Description [Line Items]
Operating lease, remaining lease term (in years)	1 year
Maximum
Lessee, Lease, Description [Line Items]
Operating lease, remaining lease term (in years)	13 years

Commitments and Contingencies_2

Commitments and Contingencies - Lease Cost and Terms (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Lease Cost
Operating lease cost	$ 0.3	$ 0.4	$ 1	$ 1
Short-term lease cost	0.1	0.3	0.3	1
Variable lease cost	0	0	0	0.1
Total lease cost	0.4	0.7	1.3	2.1
Cash paid for amounts included in the measurement of lease liabilities:
Cash paid for operating leases	0.3	0.5	1	1.6
Lessee, Lease, Description [Line Items]
Variable lease cost	$ 0	$ 0	$ 0	$ 0.1

Commitments and Contingencies_3

Commitments and Contingencies - Maturity of Operating Lease Liabilities (Details) $ in Millions	Sep. 30, 2022 USD ($)
Undiscounted cash flows
Remainder of 2022	$ 0.3
2023	1.1
2024	1
2025	1.1
2026	0.2
Thereafter	2.4
Total future minimum lease payments	6.1
Less: Imputed interest	(1)
Total	$ 5.1

Supplemental Information - Prep

Supplemental Information - Prepaid and Other Current Assets (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Prepaid and other current assets
Tax related items	$ 19	$ 17.7
Prepaid expenses	6.9	12.2
Argentina government receivable	6.3	13.3
Other receivables	7.1	2.3
Bank Acceptance Drafts	8.7	0
Derivative assets (Note 12)	1.1	0.2
Other current assets	7.4	9.6
Total	$ 56.5	$ 55.3

Supplemental Information - Othe

Supplemental Information - Other Assets (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Other assets
Argentina government receivable	$ 76.6	$ 55.8
Advance to contract manufacturers	16.3	16
Long-term raw materials inventory	1.6	4.9
Tax related items	3.8	1.3
Capitalized software, net	1.5	1.5
Other assets	12.1	11.4
Total	111.9	90.9
Argentina Government
Condensed Balance Sheet Statements, Captions [Line Items]
Export tax and export rebate receivable	$ 39.3	$ 38.4

Supplemental Information - Accr

Supplemental Information - Accrued and Other Current Liabilities (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Accrued and other current liabilities
Accrued investment in unconsolidated affiliate	$ 16.6	$ 6.2
Accrued payroll	16.5	17.1
Plant restructuring reserves	3	3.2
Advance customer payments	7.3	0
Retirement liability - 401k	2	2.5
Derivative liabilities (Note 12)	0.6	0
Environmental reserves, current	0.5	0.5
Severance related	0.2	0
Other accrued and other current liabilities	22.2	32.3
Total	$ 68.9	$ 61.8

Supplemental Information - Ot_2

Supplemental Information - Other Long-Term Liabilities (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Other long-term liabilities
Deferred compensation plan obligation	$ 5.9	$ 5.9
Contingencies related to uncertain tax positions	6.1	2.3
Self-insurance reserves	1.7	1.5
Asset retirement obligations	0.3	0.3
Contract liability - long-term	198	0
Other long-term liabilities	2.7	1.7
Total	16.7	$ 11.7
TMA Agreement, Uncertain Tax Positions
Other long-term liabilities
Contingencies related to uncertain tax positions	5.7
TMA Agreement, Indemnification Liability
Other long-term liabilities
Contingencies related to uncertain tax positions	$ 0.4